PVCT has had a rocky ride since my last post. It is now down to where it was a year ago. However the actual progress on its drug has been only positive. It is the victim of attacks by shorts who do not care about fundamentals. PVCT does not need capital for the next 15 months, so it can continue even with a low stock price. It has now announced its plans for a Phase III study for PV-10 for melanoma using standard protocols. Based on its results so far in its Phase II study (and other sources), it should do very well. [more]
PVCT announced that it had a Type C meeting with the FDA on December 16. It is not allowed to disclose the content of the meeting until it gets the official minutes, within 30 days. Those who follow this stock expect that they were granted some sort of accelerated path to approval for its lead drug, pv-10. This drug has proven effective in stage III melanoma and it has no significant side effects. It is cheap to make and easy to store and transport. It has been shown effective for other solid tumors as well. The company has flown under the radar for a long time, but this seems to be ending. The risked, discounted value of approval is many times the current price. [more]
In my opinion, both GTE (which for some reason I was just allowed to add now that it is on the AMEX but I saw that another CAPS person had it since last January) and LINE are very hot and great buys.
The problem with CAPS of course is that you cannot weight your picks and put more weight on the better picks and less on the weaker picks, like you can in your portfolio.
I cannot figure out how to change the written recommendation I have when I made this pick, so I am adding this information here: [more]